About MRM Health

MRM Health is a clinical-stage biopharma developing best-in-class Live Biotherapeutic Products for chronic inflammatory diseases with high unmet needs.

Leveraging on +20 years of cutting edge microbiome research, its CORAL® platform enables the design and manufacturing of disease-focused specific combinations of live bacteria (microbial consortia) with enhanced efficacy and scalability. In addition to advancing its lead program MH002 into pivotal clinical development in ulcerative colitis and the orphan disease indication pouchitis, MRM Health is progressing ongoing preclinical programs in other inflammatory diseases and in immune-oncology. The Company recently completed a 55M EUR Series B financing round, led by French pharmaceutical group Biocodex and with strong participation from novel investors ATHOS and BNP Paribas Fortis Private Equity and existing investors SFPIM, Ackermans & van Haaren (AvH), OMX Europe Venture Fund (OMX), Qbic II and VIB.

MH002 is currently the most advanced rationally-designed live microbial consortium therapy in Inflammatory Bowel Diseases, with positive clinical data in Phase 2a clinical trials showing safety and initial efficacy in both mild-to-moderate ulcerative colitis and in the orphan disease indication pouchitis. It was developed through MRM Health’s proprietary CORAL® technology and comprises six well-characterized and safe commensal strains, selected and optimized to tackle key disease-driving mechanisms with enhanced activity and robustness. MH002 is manufactured through the Company’s breakthrough scalable and standardized cGMP manufacturing platform, allowing for the production of complete consortia as a single drug substance. This unique ability of CORAL® to enable scalable, cost-effective manufacturing of complete optimized consortia in a single process is expected to provide both key regulatory and patient compliance advantages.